SCHEMBL27068072

SCHEMBL27068072

CC1CC(c2cccc(-n3cc(C4CC4)c4cc(CN5C[C@H](F)C[C@H](F)C5)[nH]c4c3=O)c2)(c2nncn2C)C1

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.49
▸ CBL P22681 16/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27068069 1.00 CBLB (0.49) CBLBCBL
SCHEMBL27068068 0.93 CBLB (0.50) CBLBCBL
SCHEMBL27068039 0.92 CBLB (0.48) CBLBCBL
SCHEMBL27068061 0.91 CBLB (0.51) CBLBCBL
SCHEMBL27067894 0.90 CBLB (0.49) CBLBCBL
SCHEMBL27069026 0.90 CBLB (0.49) CBLBCBL
SCHEMBL27067893 0.90 CBLB (0.49) CBLBCBL
SCHEMBL30728178 0.89 CBLB (0.54) CBLBCBL
SCHEMBL27068036 0.89 CBLB (0.49) CBLBCBL
SCHEMBL32666658 0.89 CBLB (0.51) CBLBCBL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 — — US disclosed
WO-2024020034-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC CBLB 1/4885CBL 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback